newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026

  • Liquidia Corporation will report third quarter 2026 financial results on Tuesday, November 10, 2026.
  • The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results & provide a corporate update.
  • The webcast will be available on Liquidia's website, with a rebroadcast archived for one year.
  • Liquidia focuses on respiratory & vascular diseases using its proprietary PRINT Technology.
  • YUTREPIA is approved for pulmonary arterial hypertension (PAH) & in development for Raynaud's phenomenon secondary to systemic sclerosis.
  • The company is developing L606, an investigational extended-release treprostinil formulation for PAH & pulmonary hypertension associated with interstitial lung disease.
  • Investor inquiries can be directed to Chief Business Officer Jason Adair at 919.328.4350 or Jason.adair@liquidia.com.
  • Media inquiries can be sent to media@liquidia.com.